Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices.

Sevelius JM, Deutsch MB, Grant R.

J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21105. doi: 10.7448/IAS.19.7.21105. eCollection 2016. Review.

2.

Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.

Radix A, Sevelius J, Deutsch MB.

J Int AIDS Soc. 2016 Jul 17;19(3 Suppl 2):20810. doi: 10.7448/IAS.19.3.20810. eCollection 2016. Review.

3.

Contraceptive use among HIV-infected women and men receiving antiretroviral therapy in Lusaka, Zambia: a cross-sectional survey.

Hancock NL, Chibwesha CJ, Bosomprah S, Newman J, Mubiana-Mbewe M, Sitali ES, Bolton-Moore C, Mbwili-Muleya C, Chi BH.

BMC Public Health. 2016 May 12;16:392. doi: 10.1186/s12889-016-3070-5.

4.

Temporal Trends and Predictors of Modern Contraceptive Use in Lusaka, Zambia, 2004-2011.

Hancock NL, Chibwesha CJ, Stoner MC, Vwalika B, Rathod SD, Kasaro MP, Stringer EM, Stringer JS, Chi BH.

Biomed Res Int. 2015;2015:521928. doi: 10.1155/2015/521928. Epub 2015 Dec 27.

5.

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Pyra M, Heffron R, Mugo NR, Nanda K, Thomas KK, Celum C, Kourtis AP, Were E, Rees H, Bukusi E, Baeten JM; Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams.

AIDS. 2015 Nov;29(17):2353-9. doi: 10.1097/QAD.0000000000000827.

6.

Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments.

Rowan PJ, Bhulani N.

World J Hepatol. 2015 Sep 8;7(19):2209-13. doi: 10.4254/wjh.v7.i19.2209. Review.

7.

Gonadal function and reproductive health in women with human immunodeficiency virus infection.

Yalamanchi S, Dobs A, Greenblatt RM.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):731-41. doi: 10.1016/j.ecl.2014.05.002. Review.

8.

Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya.

Hubacher D, Liku J, Kiarie J, Rakwar J, Muiruri P, Omwenga J, Chen PL.

J Int AIDS Soc. 2013 Mar 1;16:18448. doi: 10.7448/IAS.16.1.18448.

9.

Preconception and contraceptive care for women living with HIV.

Hoyt MJ, Storm DS, Aaron E, Anderson J.

Infect Dis Obstet Gynecol. 2012;2012:604183. doi: 10.1155/2012/604183. Epub 2012 Oct 11. Review.

10.

Effect of injectable contraceptive use on response to antiretroviral therapy among women in Rakai, Uganda.

Polis CB, Nakigozi G, Ssempijja V, Makumbi FE, Boaz I, Reynolds SJ, Ndyanabo A, Lutalo T, Wawer MJ, Gray RH.

Contraception. 2012 Dec;86(6):725-30. doi: 10.1016/j.contraception.2012.05.001. Epub 2012 Jun 18.

11.

Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings.

Castillo-Mancilla JR, Campbell TB.

J Comp Eff Res. 2012 Mar;1(2):157-170.

12.

High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa.

Schwartz SR, Rees H, Mehta S, Venter WD, Taha TE, Black V.

PLoS One. 2012;7(4):e36039. doi: 10.1371/journal.pone.0036039. Epub 2012 Apr 27.

13.

Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.

Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S.

Infect Dis Obstet Gynecol. 2012;2012:137192. doi: 10.1155/2012/137192. Epub 2012 Feb 28.

14.

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, Giguère P, Higgins N, Hills-Nieminen C, Kapler J, la Porte CJ, Nickel P, Park-Wyllie L, Quaia C, Robinson L, Sheehan N, Stone S, Sulz L, Yoong D.

Can J Hosp Pharm. 2012 Mar;65(2):125-45. No abstract available.

15.

Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Ouattara EN, Anglaret X, Wong AY, Chu J, Hsu HE, Danel C, Eholié S, Moh R, Gabillard D, Walensky RP, Freedberg KA.

AIDS. 2012 Mar 13;26(5):625-34. doi: 10.1097/QAD.0b013e328350fbfb.

16.

Care of the human immunodeficiency virus-infected menopausal woman.

Cejtin HE.

Am J Obstet Gynecol. 2012 Aug;207(2):87-93. doi: 10.1016/j.ajog.2011.12.031. Epub 2011 Dec 30. Review.

17.

Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi.

Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, Chintedze J, Malunga G, Hosseinipour M, Cohen MS, Stanczyk FZ, Kashuba AD.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e40-3. doi: 10.1097/QAI.0b013e31822b8bf8. No abstract available.

18.

The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection.

Schafer JJ, Ravi S, Rowland EV, Shenoda G, Leon N.

P T. 2011 Jun;36(6):346-64. No abstract available.

19.

Contraception in HIV-positive female adolescents.

Kancheva Landolt NT, Lakhonphon S, Ananworanich J.

AIDS Res Ther. 2011 Jun 1;8(1):19. doi: 10.1186/1742-6405-8-19.

20.

Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):473-82. doi: 10.1097/QAI.0b013e3181eb5ff5.

Supplemental Content

Support Center